Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326906 | 1.00 | SLC2A1 (0.47) | SLC2A1KCNH2HTR1ADRD2KDM1A | |
| SCHEMBL3146445 | 1.00 | SLC2A1 (0.47) | SLC2A1KCNH2HTR1ADRD2KDM1A | |
| Hydrochloric Acid SCHEMBL3149069 | 0.99 | SLC2A1 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL3224644 | 0.91 | SLC2A1 (0.40) | SLC2A1KCNH2KDM1A | |
| SCHEMBL3149404 | 0.85 | SLC2A1 (0.44) | SLC2A1KCNH2 | |
| SCHEMBL3144391 | 0.85 | SLC2A1 (0.44) | SLC2A1KCNH2HTR1ADRD2 | |
| SCHEMBL3144383 | 0.85 | SLC2A1 (0.44) | SLC2A1KCNH2HTR1ADRD2 | |
| SCHEMBL3394012 | 0.85 | SLC2A1 (0.46) | SLC2A1KCNH2HTR1ADRD2 | |
| SCHEMBL3142143 | 0.85 | SLC2A1 (0.43) | SLC2A1KCNH2HTR1ADRD2 | |
| SCHEMBL3149951 | 0.85 | SLC2A1 (0.43) | SLC2A1KCNH2HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-1954697-B1 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | NRDC, NACA, NOP2 | SLC2A1 4498/4885KCNH2 2974/4885HTR1A 3065/4885 |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | SLC2A1 4630/4885KCNH2 784/4885HTR1A 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.